Nutrition 21 Study Results Boost Stock Price

Nutrition 21 Study Results Boost Stock Price

PURCHASE, N.Y.Nutrition 21 saw a surge in stock value in late August after two studies using the companys patented chromium picolinate products were presented at the International Diabetes Federation (IDF) Congress in Paris. The stock (NASDAQ:NXXI) was up 153 percent to $1.34 on Aug. 28, the day the studies were presented, with composite volume of about 14.1 million shares, compared to an average daily volume of 185,819 shares.

The study, which gained major U.S. press, saw 30 people with Type II diabetes significantly reduce their elevated blood sugar levels over 12 weeks through use of diet and diabetes counseling, glucose monitoring, and use of Nutrition 21s Diachrome, a combination of chromium picolinate and biotin. The effects will be tested in a 600- patient, double blind, placebo-controlled clinical study to be conducted through Diabetex, a diabetes management company; Nutrition 21 expects the trial to be completed in June 2004.

The second clinical trial presented in Paris found Nutrition 21s Chromax chromium picolinate significantly increased insulin sensitivity in Type II diabetics. The double blind, placebo-controlled trial used 1,000 mcg/d of Chromax or placebo; subjects taking chromium picolinate had a mean increase in insulin sensitivity of 8.9 percent, compared to a mean decrease of 3.6 percent in the placebo group.

By applying rigorous science, we hope to show chromiums potential to improve the quality of patient care for people with diabetes and reduce cost of therapy, said James Komorowski, Nutrition 21s vice president of technical services and scientific affairs. This new research further supports the large body of scientific evidence showing chromium picolinate is a safe and effective addition to the diet for people with Type II diabetes seeking optimal control of their blood sugar levels.

For more information, visit www.nutrition21.com or Booth #1334- 1336 at SupplySide West.